DENVER and SAN FRANCISCO, Aug. 16, 2023 /PRNewswire/ -- Core Biotherapeutics, a platform biotech company focused on creating the next generation of drugs to transform the lives of patients with cancer and other life-threatening diseases, has entered into a collaboration with the University of Colorado Anschutz Medical Campus (CU Anschutz) to expand the benefits of their therapeutic approach to Acute Myeloid Leukemia (AML) patients. This partnership was facilitated by CU Innovations, the CU Anschutz department tasked with bringing together industry partners, entrepreneurs, investors, and CU Anschutz researchers to translate technology to improve outcomes for patients worldwide.
DENVER, CO / ACCESSWIRE / July 17, 2023 / Laxxon Medical, a leading 3D screen printing pharma-technology company, announced today their strategic partnership with CU Innovations at the University of Colorado Anschutz Medical Campus (CU Anschutz). The partnership will create an opportunity for researchers at CU Anschutz to develop novel drug therapies using Laxxon's 3D screen printing technology, SPID®-Technology (Screen Printing Innovational Drug Technology).
The SPARK | REACH Program is the go-to program on campus for anyone who has promising proof-of-concept data in the lab. SPARK helps develop technologies that address unmet medical needs and will open for new applications on June 19.
The event was sponsored by CU Innovations, the university’s bridge between cutting-edge technologies developed on campus and industry partners, entrepreneurs and investors. It was held in the Donald M. Elliman Conference Center in the Anschutz Health Sciences Building.
CU Innovations offers an exceptional experience for graduate students, providing them with the opportunity to immerse themselves in the department and become valuable contributors to the CU Anschutz Medical Campus innovation ecosystem.